218. Alport syndrome Clinical trials / Disease details

Clinical trials : 26 / Drugs : 33 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 29

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00309257 (ClinicalTrials.gov)	January 2004	30/3/2006	Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome	Alport Syndrome	Drug: ACE I, ATA II and Statins;Drug: Benazepril , Valsartan and Fluvastatin	Mario Negri Institute for Pharmacological Research	NULL	Completed	15 Years	70 Years	Both	9	Phase 2	Italy
2	NCT02378805 (ClinicalTrials.gov)	July 1995	26/2/2015	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies	Thin Basement Membrane Disease;Familial Benign Hematuria;Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease	Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol	University Hospital Goettingen	Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine	Recruiting	N/A	N/A	All	500		Germany